Collaboration of Hprt/K-RAS/c-Myc mutation in the oncogenesis of T-lymphocytic leukemia: a comparative study
Aim: Leukemia is a malignant clonal illness stem from the mutations of hematopoietic cells. Acute lymphoblastic leukemia is one of the utmost prevalent kinds of leukemia, is brought on by atypical lymphoid progenitor cell division in the bone marrow. Materials & methods: A comparative study betw...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Future Science OA |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.2144/fsoa-2023-0111 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849319111636549632 |
|---|---|
| author | Mai O Kadry Abdel-Hamid Z Abdel Hamid Rehab M Abdel-Megeed |
| author_facet | Mai O Kadry Abdel-Hamid Z Abdel Hamid Rehab M Abdel-Megeed |
| author_sort | Mai O Kadry |
| collection | DOAJ |
| description | Aim: Leukemia is a malignant clonal illness stem from the mutations of hematopoietic cells. Acute lymphoblastic leukemia is one of the utmost prevalent kinds of leukemia, is brought on by atypical lymphoid progenitor cell division in the bone marrow. Materials & methods: A comparative study between, titanium Nanoparticle-loaded doxorubicin or cisplatin and lactoferrin-loaded doxorubicin or cisplatin, on 7,12-dimethylbenz[a]-anthracene (DMBA)-induced leukemia was investigated and confirming the hypothesis that messenger RNA of Hprt/K-RAS/c-Myc/SAT-2/P53/JAK-2 is a forthcoming signaling pathways in leukemia. Results: A significant alteration in Hprt, K-RAS, C-Myc, P53, JAK-2 and SAT-2 genes was observed post DMBA intoxication the aforementioned Nanodrugs modulated these signaling pathways. Conclusion: The carrier-loaded drugs triggered cytotoxicity of cancer cells via enhancing drug efficacy and bio-availability. |
| format | Article |
| id | doaj-art-a11f4ea4adc249ce89a79bd964c7c2fd |
| institution | Kabale University |
| issn | 2056-5623 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Future Science OA |
| spelling | doaj-art-a11f4ea4adc249ce89a79bd964c7c2fd2025-08-20T03:50:38ZengTaylor & Francis GroupFuture Science OA2056-56232024-12-0110110.2144/fsoa-2023-0111Collaboration of Hprt/K-RAS/c-Myc mutation in the oncogenesis of T-lymphocytic leukemia: a comparative studyMai O Kadry0Abdel-Hamid Z Abdel Hamid1Rehab M Abdel-Megeed2National Research Center, Therapeutic Chemistry Deparment, Al Bhoouth Street, EgyptNational Research Center, Therapeutic Chemistry Deparment, Al Bhoouth Street, EgyptNational Research Center, Therapeutic Chemistry Deparment, Al Bhoouth Street, EgyptAim: Leukemia is a malignant clonal illness stem from the mutations of hematopoietic cells. Acute lymphoblastic leukemia is one of the utmost prevalent kinds of leukemia, is brought on by atypical lymphoid progenitor cell division in the bone marrow. Materials & methods: A comparative study between, titanium Nanoparticle-loaded doxorubicin or cisplatin and lactoferrin-loaded doxorubicin or cisplatin, on 7,12-dimethylbenz[a]-anthracene (DMBA)-induced leukemia was investigated and confirming the hypothesis that messenger RNA of Hprt/K-RAS/c-Myc/SAT-2/P53/JAK-2 is a forthcoming signaling pathways in leukemia. Results: A significant alteration in Hprt, K-RAS, C-Myc, P53, JAK-2 and SAT-2 genes was observed post DMBA intoxication the aforementioned Nanodrugs modulated these signaling pathways. Conclusion: The carrier-loaded drugs triggered cytotoxicity of cancer cells via enhancing drug efficacy and bio-availability.https://www.tandfonline.com/doi/10.2144/fsoa-2023-0111c-MycDMBAHprtJAK2K-RASleukemia |
| spellingShingle | Mai O Kadry Abdel-Hamid Z Abdel Hamid Rehab M Abdel-Megeed Collaboration of Hprt/K-RAS/c-Myc mutation in the oncogenesis of T-lymphocytic leukemia: a comparative study Future Science OA c-Myc DMBA Hprt JAK2 K-RAS leukemia |
| title | Collaboration of Hprt/K-RAS/c-Myc mutation in the oncogenesis of T-lymphocytic leukemia: a comparative study |
| title_full | Collaboration of Hprt/K-RAS/c-Myc mutation in the oncogenesis of T-lymphocytic leukemia: a comparative study |
| title_fullStr | Collaboration of Hprt/K-RAS/c-Myc mutation in the oncogenesis of T-lymphocytic leukemia: a comparative study |
| title_full_unstemmed | Collaboration of Hprt/K-RAS/c-Myc mutation in the oncogenesis of T-lymphocytic leukemia: a comparative study |
| title_short | Collaboration of Hprt/K-RAS/c-Myc mutation in the oncogenesis of T-lymphocytic leukemia: a comparative study |
| title_sort | collaboration of hprt k ras c myc mutation in the oncogenesis of t lymphocytic leukemia a comparative study |
| topic | c-Myc DMBA Hprt JAK2 K-RAS leukemia |
| url | https://www.tandfonline.com/doi/10.2144/fsoa-2023-0111 |
| work_keys_str_mv | AT maiokadry collaborationofhprtkrascmycmutationintheoncogenesisoftlymphocyticleukemiaacomparativestudy AT abdelhamidzabdelhamid collaborationofhprtkrascmycmutationintheoncogenesisoftlymphocyticleukemiaacomparativestudy AT rehabmabdelmegeed collaborationofhprtkrascmycmutationintheoncogenesisoftlymphocyticleukemiaacomparativestudy |